Patents by Inventor Alfred S. Lewin
Alfred S. Lewin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240101607Abstract: Disclosed are methods and compositions for preventing, treating, and/or ameliorating one or more symptoms of inflammation in a mammal. In particular, viral vectors and medicaments containing them are disclosed, which are useful in the prophylaxis, therapy, or amelioration of symptoms of one or more inflammatory-mediated mammalian diseases, such as age-related macular degeneration (AMD), arthritis, Bechet's disease, Best macular dystrophy, corneal inflammation, diabetic retinopathy, drusen formation, dry AMD, dry eye, geographic atrophy, glaucomaocular neovascularization, Lupus erythematosus, macular degeneration, Mallatia Leventinese and Doyne honeycomb retinal dystrophy, nephritis, ocular hypertension, ocular inflammation, recurrent uveitis, Sorsby fundus dystrophy, vasculitis, vitreoretinopathy, wet AMD, or related disorders.Type: ApplicationFiled: May 9, 2023Publication date: March 28, 2024Applicant: University of Florida Research Foundation, IncorporatedInventors: Douglas Grant McFadden, Alfred S. Lewin, Alexandra Rose Lucas, Cristhian J. Ildefonso, Mohammed Masmudur Rahman
-
Patent number: 11739130Abstract: The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or ocular inflammation. In an exemplary embodiment, a method is disclosed that involves administering an expression vector that delivers a secretable and cell penetrating CARD to a subject in need of treatment or prevention of age-related macular degeneration or another condition involving macular degeneration or ocular neovascularization.Type: GrantFiled: March 17, 2021Date of Patent: August 29, 2023Assignee: University of Florida Research Foundation, IncorporatedInventors: Cristhian J. Ildefonso, Alfred S. Lewin, Qiuhong Li
-
Patent number: 11685767Abstract: Disclosed are methods and compositions for preventing, treating, and/or ameliorating one or more symptoms of inflammation in a mammal. In particular, viral vectors and medicaments containing them are disclosed, which are useful in the prophylaxis, therapy, or amelioration of symptoms of one or more inflammatory-mediated mammalian diseases, such as age-related macular degeneration (AMD), arthritis, Bechet's disease, Best macular dystrophy, corneal inflammation, diabetic retinopathy, drusen formation, dry AMD, dry eye, geographic atrophy, glaucomaocular neovascularization, Lupus erythematosus, macular degeneration, Mallatia Leventinese and Doyne honeycomb retinal dystrophy, nephritis, ocular hypertension, ocular inflammation, recurrent uveitis, Sorsby fundus dystrophy, vasculitis, vitreoretinopathy, wet AMD, or related disorders.Type: GrantFiled: September 9, 2016Date of Patent: June 27, 2023Assignee: University of Florida Research Foundation, IncorporatedInventors: Douglas Grant McFadden, Alfred S. Lewin, Alexandra Rose Lucas, Cristhian J. Ildefonso, Mohammed Masmudur Rahman
-
Publication number: 20230132355Abstract: The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or ocular inflammation. In an exemplary embodiment, a method is disclosed that involves administering an expression vector that delivers a secretable and cell penetrating CARD to a subject in need of treatment or prevention of age-related macular degeneration or another condition involving macular degeneration or ocular neovascularization.Type: ApplicationFiled: March 17, 2021Publication date: April 27, 2023Applicant: University of Florida Research Foundation, IncorporatedInventors: Cristhian J. Ildefonso, Alfred S. Lewin, Qiuhong Li
-
Publication number: 20220380808Abstract: Aspects of the application relate to methods and compositions for delivering therapeutic nucleic acids to neural cells or tissue in a subject. Additional aspects of the application relate to therapeutic nucleic acids, for example therapeutic ribozymes, that are useful for inhibiting viral reactivation in a subject.Type: ApplicationFiled: May 6, 2022Publication date: December 1, 2022Applicants: University of Florida Research Foundation, Incorporated, Board of Supervisors of Louisiana State University & Agricultural & Mechanical CollegeInventors: David C. Bloom, Alfred S. Lewin, Donna M. Newmann, Zachary L. Watson, Sonal Sanjeev Tuli, Gregory Scott Schultz
-
Patent number: 11512326Abstract: The present invention is directed to a delivery vector for transferring a small peptide coding sequence to a cell for expression of the small peptide coding sequence within the cell. The delivery vector comprises a secretory signal sequence; a sequence encoding a carrier protein operatively associated with the secretory signal sequence; a sequence encoding a cleavage site operatively associated with the sequence encoding a carrier protein; and a sequence encoding a small peptide operatively associated with the sequence encoding a cleavage site.Type: GrantFiled: May 26, 2010Date of Patent: November 29, 2022Assignee: University of Florida Research Foundation, IncorporatedInventors: Qiuhong Li, William W. Hauswirth, Alfred S. Lewin
-
Patent number: 11351273Abstract: Aspects of the application relate to methods and compositions for delivering therapeutic nucleic acids to neural cells or tissue in a subject. Additional aspects of the application relate to therapeutic nucleic acids, for example therapeutic ribozymes, that are useful for inhibiting viral reactivation in a subject.Type: GrantFiled: June 21, 2017Date of Patent: June 7, 2022Assignees: Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College, University of Florida Research Foundation, IncorporatedInventors: David C. Bloom, Alfred S. Lewin, Donna M. Neumann, Zachary L. Watson, Sonal Sanjeev Tuli, Gregory Scott Schultz
-
Publication number: 20220033826Abstract: Aspects of the disclosure relate to methods and compositions useful for treating bestrophinopathies, such as Best Disease.Type: ApplicationFiled: August 30, 2019Publication date: February 3, 2022Applicant: University of Florida Research Foundation, IncorporatedInventors: William W. Hauswirth, Alfred S. Lewin, Cristhian J. Ildefonso, Brianna M. Young
-
Publication number: 20210371481Abstract: The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or ocular inflammation. In an exemplary embodiment, a method is disclosed that involves administering an expression vector that delivers a secretable and cell penetrating CARD to a subject in need of treatment or prevention of age-related macular degeneration or another condition involving macular degeneration or ocular neovascularization.Type: ApplicationFiled: March 17, 2021Publication date: December 2, 2021Applicant: University of Florida Research Foundation, IncorporatedInventors: Cristhian J. Ildefonso, Alfred S. Lewin, Qiuhong Li
-
Publication number: 20210324387Abstract: Aspects of the disclosure relate to methods and compositions for treating retinitis pigmentosa. In some aspects, the disclosure provides compositions and methods for delivering an interfering nucleic acid (for example an interfering RNA) to a subject in order to reduce expression of one or both alleles of an endogenous rho gene (for example a mutant rho allele associated with retinitis pigmentosa) in the subject. In some embodiments, a replacement rho gene that is resistant to the interfering nucleic acid also is delivered to the subject.Type: ApplicationFiled: May 21, 2021Publication date: October 21, 2021Applicants: Univeristy of Florida Research Foundation, Incorporated, The Trustees of the University of PennsylvaniaInventors: Alfred S. Lewin, William W. Hauswirth, Michael T. Massengill, William Beltran, Gustavo D. Aguirre, Artur Cideciyan, Samuel Jacobson
-
Publication number: 20210300978Abstract: The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or inflammation, including ocular inflammation. In some embodiments, the methods comprise administering an expression vector that delivers a secretable and cell penetrating Nrf2 to a subject in need thereof.Type: ApplicationFiled: June 8, 2021Publication date: September 30, 2021Applicant: University of Florida Research Foundation, IncorporatedInventors: Cristhian J. Ildefonso, Alfred S. Lewin, Qiuhong Li
-
Patent number: 11118185Abstract: Aspects of the disclosure relate to methods and compositions for treating retinitis pigmentosa. In some aspects, the disclosure provides compositions and methods for delivering an interfering nucleic acid (for example an interfering RNA) to a subject in order to reduce expression of one or both alleles of an endogenous rho gene (for example a mutant rho allele associated with retinitis pigmentosa) in the subject. In some embodiments, a replacement rho gene that is resistant to the interfering nucleic acid also is delivered to the subject.Type: GrantFiled: March 1, 2017Date of Patent: September 14, 2021Assignees: University of Florida Research Foundation, Incorporated, The Trustees of the University of PennsylvaniaInventors: Alfred S. Lewin, William W. Hauswirth, Michael T. Massengill, William Beltran, Gustavo D. Aguirre, Artur Cideciyan, Samuel Jacobson
-
Publication number: 20210207147Abstract: Aspects of the disclosure relate to methods and compositions useful for treating retinitis pigmentosa. In some aspects, the disclosure provides compositions and methods for delivering an interfering RNA to a subject in order to reduce expression of one or both alleles of an endogenous RHO gene (for example a mutant rho allele associated with retinitis pigmentosa) in a subject. In some embodiments, a replacement RHO coding sequence that is resistant to the interfering RNA also is delivered to the subject.Type: ApplicationFiled: June 3, 2019Publication date: July 8, 2021Applicants: University of Florida Research Foundation, Incorporated, The Trustees of the University of PennsylvaniaInventors: Alfred S. Lewin, William W. Hauswirth, Michael T. Massengill, William Beltran, Gustavo D. Aguirre, Artur Cideciyan, Samuel Jacobson
-
Patent number: 11053291Abstract: The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or inflammation, including ocular inflammation. In some embodiments, the methods comprise administering an expression vector that delivers a secretable and cell penetrating Nrf2 to a subject in need thereof.Type: GrantFiled: February 19, 2015Date of Patent: July 6, 2021Assignee: University of Florida Research Foundation, IncorporatedInventors: Cristhian J. Ildefonso, Alfred S. Lewin, Qiuhong Li
-
Patent number: 10981961Abstract: The present invention provides methods and compositions for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, ocular neovascularization, or ocular inflammation. In an exemplary embodiment, a method is disclosed that involves administering an expression vector that delivers a secretable and cell penetrating CARD to a subject in need of treatment or prevention of age-related macular degeneration or another condition involving macular degeneration or ocular neovascularization.Type: GrantFiled: March 11, 2014Date of Patent: April 20, 2021Assignee: University of Florida Research Foundation, IncorporatedInventors: Cristhian J. Ildefonso, Alfred S. Lewin, Qiuhong Li
-
Publication number: 20210000973Abstract: In some aspects, the disclosure relates to compositions and methods that are useful for treating inflammatory disorders and conditions. In some embodiments, the disclosure provides recombinant adeno-associated virus (rAAV) vectors and particles encoding a transgene that expresses a Myxomavirus serine proteinase inhibitor (Serp) protein (e.g., Serp-1) and methods for treating inflammatory disorders using the same.Type: ApplicationFiled: March 8, 2019Publication date: January 7, 2021Applicant: University of Florida Research Foundation, IncorporatedInventors: Alexandra Rose Lucas, Alfred S. Lewin, Cristhian J. Ildefonso
-
Patent number: 10383922Abstract: Described herein are methods of preventing, arresting progression of or ameliorating vision loss and other conditions associated with retinitis pigmentosa and x-linked retinitis pigmentosa in a subject. The methods include administering to the subject an effective concentration of a composition comprising a recombinant adeno-associated virus (AAV) carrying a nucleic acid sequence encoding a normal retinitis pigmentosa GTPase regulator (RPGR gene), or fragment thereof, under the control of regulatory sequences which express the product of the gene in the photoreceptor cells of the subject, and a pharmaceutically acceptable carrier.Type: GrantFiled: September 8, 2017Date of Patent: August 20, 2019Assignees: The Trustees of the University of Pennsylvania, University of Florida Research Foundation, IncorporatedInventors: William A Beltran, Gustavo D Aguirre, Samuel G Jacobson, Artur V Cideciyan, Alfred S Lewin, Sanford L Boye, William W Hauswirth, Wen-Tao Deng
-
Publication number: 20190231902Abstract: Aspects of the application relate to methods and compositions for delivering therapeutic nucleic acids to neural cells or tissue in a subject. Additional aspects of the application relate to therapeutic nucleic acids, for example therapeutic ribozymes, that are useful for inhibiting viral reactivation in a subject.Type: ApplicationFiled: June 21, 2017Publication date: August 1, 2019Applicants: University of Florida Research Foundation, Incorporated, Board of Supervisors of Louisiana State University & Agricultural & Mechanical CollegeInventors: David C. Bloom, Alfred S. Lewin, Donna M. Neumann, Zachary L. Watson, Sonal Sanjeev Tuli, Gregory Scott Schultz
-
Publication number: 20190093111Abstract: Aspects of the disclosure relate to methods and compositions for treating retinitis pigmentosa. In some aspects, the disclosure provides compositions and methods for delivering an interfering nucleic acid (for example an interfering RNA) to a subject in order to reduce expression of one or both alleles of an endogenous rho gene (for example a mutant rho allele associated with retinitis pigmentosa) in the subject. In some embodiments, a replacement rho gene that is resistant to the interfering nucleic acid also is delivered to the subject.Type: ApplicationFiled: March 1, 2017Publication date: March 28, 2019Applicants: University of Florida Research Foundation, Incorporated, The Trustees of the University of PennsylvaniaInventors: Alfred S. Lewin, William W. Hauswirth, MIchael T. Massengill, William Beltran, Gustavo D. Aguirre, Artur Cideciyan, Samuel Jacovson
-
Publication number: 20180036385Abstract: Described herein are methods of preventing, arresting progression of or ameliorating vision loss and other conditions associated with retinitis pigmentosa and x-linked retinitis pigmentosa in a subject. The methods include administering to said subject an effective concentration of a composition comprising a recombinant adeno-associated virus (AAV) carrying a nucleic acid sequence encoding a normal retinitis pigmentosa GTPase regulator (RPGR gene), or fragment thereof, under the control of regulatory sequences which express the product of the gene in the photoreceptor cells of the subject, and a pharmaceutically acceptable carrier.Type: ApplicationFiled: September 8, 2017Publication date: February 8, 2018Inventors: William A. BELTRAN, Gustavo D. AGUIRRE, Samuel G. JACOBSON, Artur V. CIDECIYAN, Alfred S. LEWIN, Sanford L. BOYE, William W. HAUSWIRTH, Wen-Tao DENG